DERM
Price
$6.95
Change
-$0.31 (-4.27%)
Updated
Aug 15 closing price
Capitalization
169.43M
80 days until earnings call
SWGHF
Price
$11.52
Change
-$1.88 (-14.03%)
Updated
Apr 7 closing price
Capitalization
1.54B
Interact to see
Advertisement

DERM vs SWGHF

Header iconDERM vs SWGHF Comparison
Open Charts DERM vs SWGHFBanner chart's image
Journey Medical
Price$6.95
Change-$0.31 (-4.27%)
Volume$268.83K
Capitalization169.43M
SAWAI GROUP
Price$11.52
Change-$1.88 (-14.03%)
Volume$120
Capitalization1.54B
DERM vs SWGHF Comparison Chart in %
Loading...
DERM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DERM vs. SWGHF commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DERM is a Hold and SWGHF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (DERM: $6.95 vs. SWGHF: $11.52)
Brand notoriety: DERM: Notable vs. SWGHF: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: DERM: 153% vs. SWGHF: 100%
Market capitalization -- DERM: $169.43M vs. SWGHF: $1.54B
DERM [@Pharmaceuticals: Generic] is valued at $169.43M. SWGHF’s [@Pharmaceuticals: Generic] market capitalization is $1.54B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DERM’s FA Score shows that 0 FA rating(s) are green whileSWGHF’s FA Score has 1 green FA rating(s).

  • DERM’s FA Score: 0 green, 5 red.
  • SWGHF’s FA Score: 1 green, 4 red.
According to our system of comparison, DERM is a better buy in the long-term than SWGHF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DERM’s TA Score shows that 3 TA indicator(s) are bullish.

  • DERM’s TA Score: 3 bullish, 6 bearish.

Price Growth

DERM (@Pharmaceuticals: Generic) experienced а -8.19% price change this week, while SWGHF (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

DERM is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SWGHF($1.54B) has a higher market cap than DERM($169M). DERM has higher P/E ratio than SWGHF: DERM (39.08) vs SWGHF (15.65). DERM YTD gains are higher at: 77.749 vs. SWGHF (-14.030). SWGHF has higher annual earnings (EBITDA): 36B vs. DERM (-1.43M). SWGHF has more cash in the bank: 51.4B vs. DERM (21.1M). DERM has less debt than SWGHF: DERM (25.2M) vs SWGHF (93.4B). SWGHF has higher revenues than DERM: SWGHF (177B) vs DERM (56.2M).
DERMSWGHFDERM / SWGHF
Capitalization169M1.54B11%
EBITDA-1.43M36B-0%
Gain YTD77.749-14.030-554%
P/E Ratio39.0815.65250%
Revenue56.2M177B0%
Total Cash21.1M51.4B0%
Total Debt25.2M93.4B0%
FUNDAMENTALS RATINGS
DERM vs SWGHF: Fundamental Ratings
DERM
SWGHF
OUTLOOK RATING
1..100
2539
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
4575
P/E GROWTH RATING
1..100
4386
SEASONALITY SCORE
1..100
3950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SWGHF's Valuation (12) in the null industry is somewhat better than the same rating for DERM (74) in the Biotechnology industry. This means that SWGHF’s stock grew somewhat faster than DERM’s over the last 12 months.

SWGHF's Profit vs Risk Rating (100) in the null industry is in the same range as DERM (100) in the Biotechnology industry. This means that SWGHF’s stock grew similarly to DERM’s over the last 12 months.

SWGHF's SMR Rating (97) in the null industry is in the same range as DERM (97) in the Biotechnology industry. This means that SWGHF’s stock grew similarly to DERM’s over the last 12 months.

DERM's Price Growth Rating (45) in the Biotechnology industry is in the same range as SWGHF (75) in the null industry. This means that DERM’s stock grew similarly to SWGHF’s over the last 12 months.

DERM's P/E Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for SWGHF (86) in the null industry. This means that DERM’s stock grew somewhat faster than SWGHF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DERMSWGHF
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
N/A
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
83%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
7%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
8%
Advances
ODDS (%)
Bullish Trend 7 days ago
88%
N/A
Declines
ODDS (%)
Bearish Trend 17 days ago
87%
N/A
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
88%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
DERM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HNCRX20.550.09
+0.44%
Hartford International Growth R3
QUASX62.850.05
+0.08%
AB Small Cap Growth A
SZCCX39.69-0.06
-0.15%
DWS Small Cap Core C
FCLKX17.49-0.04
-0.23%
Fidelity Large Cap Stock K6
JRASX91.88-0.24
-0.26%
Janus Henderson Research S

DERM and

Correlation & Price change

A.I.dvisor tells us that DERM and AQST have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DERM and AQST's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DERM
1D Price
Change %
DERM100%
-4.27%
AQST - DERM
27%
Poorly correlated
N/A
SWGHF - DERM
25%
Poorly correlated
N/A
ETON - DERM
23%
Poorly correlated
+2.04%
YCBD - DERM
22%
Poorly correlated
-10.98%
CRDL - DERM
22%
Poorly correlated
-2.24%
More

SWGHF and

Correlation & Price change

A.I.dvisor tells us that SWGHF and MEDIF have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SWGHF and MEDIF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SWGHF
1D Price
Change %
SWGHF100%
N/A
MEDIF - SWGHF
29%
Poorly correlated
-7.67%
DERM - SWGHF
25%
Poorly correlated
-4.27%
STEK - SWGHF
21%
Poorly correlated
+0.55%
AAWH - SWGHF
16%
Poorly correlated
+1.72%
GLASF - SWGHF
4%
Poorly correlated
-6.40%
More